[Molecular taxonomy of luminal breast cancer in 2015].
Luminal breast cancers (i.e. displaying œstrogen receptor expression) account for 70 to 80% of all breast cancers. It encompasses a heterogeneous population of tumors, differing by their clinical course, histopathological characteristics, phenotypes and molecular features. As a continuum of lesions, luminal breast tumors are critically challenged by the recent evolution in treatment decision making. Indeed, whilst about half of luminal breast cancers are associated with a very good prognosis (so-called luminal A tumors with regard to the intrinsic molecular classification), 20% of luminal tumors display a poor clinical outcome (i.e. luminal B tumors), the remaining tumors corresponding to intermediate lesions that are very difficult to accurately classify. Clearly, therapeutic issues are critical, since according to the vast majority of international consensus guidelines luminal A tumors are best treated by endocrine therapy, whilst an additional adjuvant chemotherapy will be proposed to patients harbouring luminal B breast cancer. By providing precise histopathological, phenotypic and molecular characterization of luminal breast tumors, the pathologist is actually the cornerstone of this therapeutic decision. Herein we aim to review the state-of-the-art knowledge on luminal breast carcinomas, with a perspective of routine clinical practice in 2015.